Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 32Breast Neoplasms 25Fallopian Tube Neoplasms 21Multiple Myeloma 18Carcinoma, Ovarian Epithelial 14Lymphoma 8Triple Negative Breast Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hodgkin Disease 3Prostatic Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Burkitt Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Patient Participation 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1

Interventions

pembrolizumab 2MLN 8237 2pemigatinib 1liposomal doxorubicin 1cabiralizumab 1Nivolumab 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Malignancies × liposomal doxorubicin × Clear all
NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

AstraZeneca

Phase 1/2 Completed
30 enrolled 17 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡